International phase 3 clinical trial for new melanoma treatment recruits first patients
The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda
Read More
Tag: melanoma
First UK patients receive experimental mRNA therapy for cancer in global trial
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
Read More
Immune cell helps predict skin cancer patients’ responses to immunotherapies
Vd1-gd T cells were effective in predicting positive responses to ICI therapy
Read More
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients
At six and a half years 49% of patients treated with combination therapy remained alive
Read More
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma
RELATIVITY-047 trial met primary endpoint of progression-free survival
Read More
BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma
Combination treatment did not achieve statistical significance in all-comer population
Read More
Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma
Over half of patients treated with combination therapy were alive and relapse-free after five years
Read More
Novartis’ melanoma combo fails in PhIII
The study assessed investigational immunotherapy spartalizumab (PDR001) in combination with targeted therapies Tafinlar and Mekinist
Read More
Skin cancer deaths rocket 70% since the 1970s
Melanoma incidence rates have more than doubled in the UK
Read More
Skin cancer rates rocket 45% in 10 years
Rates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men.
Read More
UK regulatory approval for SCIB1 phase II advanced melanoma trial
The study is designed to assess whether the addition of SCIB1 treatment will result in an improvement in the tumour response rate.
Read More
NICE OK for Braftovi skin cancer drug
The National Institute for Health and Care Excellence (NICE) has recommended Pierre Fabre’s Braftovi and Mektovi combination as an option for some people with melanoma.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
